The Hemoglobin Glycation Index Predicts the Risk of Adverse Cardiovascular Events in Coronary Heart Disease Patients with Type 2 Diabetes Mellitus

Overview

Journal Front Cardiovasc Med

Specialty Cardiology & Vascular Diseases

Date 2022 Nov 21

PMID 36407464

Authors

Shuai Xu

Zhen Qin

Ruixia Yuan

Xiaolin Cui

Li Zhang

Jing Bai

Gangqiong Liu

Zeyu Wang

Fengyi Yu

Yan Lv

Jinying Zhang

Junnan Tang

Affiliations

Soon will be listed here.

Abstract

Background: Previous studies have shown that the hemoglobin glycation index (HGI) can be used as a predictor of diabetic complications. However, limited information is currently available to indicate the correlation between HGI and comorbidity of coronary heart disease (CHD) and diabetes. This study aimed to evaluate the potential of HGI to predict major adverse cardiovascular events (MACEs) in CHD patients with type 2 diabetes mellitus (T2DM) undergoing percutaneous coronary intervention (PCI).

Materials And Methods: A total of 918 CHD patients with T2DM were enrolled in a 3-year retrospective cohort study, from December 2017 to December 2020 at the First Affiliated Hospital of Zhengzhou University. Data including fasting blood glucose (FPG/FBG) and glycated hemoglobin A1c (HbA1c) were collected. HGI was calculated as actual measured HbA1c minus predicted HbA1c. Three groups were further divided based on the levels of HGI, including low, medium, and high levels.

Result: Kaplan Meier analysis indicated that elevated HGI was strongly associated with the occurence of MACE (log-rank < 0.001). Multivariate Cox regression analysis revealed that elevated HGI was an independent risk factor for incident MACE in CHD patients with T2DM [adjusted hazard ratio (HR): 1.473; 95% confidence interval (CI): 1.365-1.589, < 0.001].

Conclusions: Hemoglobin glycation index is an independent predictor of MACE events in CHD patients with T2DM. High HGI indicates a higher risk of MACE occurrence.

Citing Articles

Association between the haemoglobin glycation index (HGI) and clinical outcomes in patients with acute decompensated heart failure.

Cheng W, Huang R, Pu Y, Li T, Bao X, Chen J Ann Med. 2024; 56(1):2330615.

PMID: 38513606 PMC: 10962296. DOI: 10.1080/07853890.2024.2330615.

Time in range and complications of diabetes: a cross-sectional analysis of patients with Type 1 diabetes.

Bezerra M, Neves C, Neves J, Carvalho D Diabetol Metab Syndr. 2023; 15(1):244.

PMID: 38008747 PMC: 10680248. DOI: 10.1186/s13098-023-01219-2.

Association between hemoglobin glycation index and non-alcoholic fatty liver disease in the patients with type 2 diabetes mellitus.

Wang M, Li S, Zhang X, Li X, Cui J J Diabetes Investig. 2023; 14(11):1303-1311.

PMID: 37551797 PMC: 10583654. DOI: 10.1111/jdi.14066.

References

Hempe J, Gomez R, McCarter Jr R, Chalew S . High and low hemoglobin glycation phenotypes in type 1 diabetes: a challenge for interpretation of glycemic control. J Diabetes Complications. 2002; 16(5):313-20. DOI: 10.1016/s1056-8727(01)00227-6. View

Zhang C, Jiang L, Xu L, Tian J, Liu J, Zhao X . Implications of N-terminal pro-B-type natriuretic peptide in patients with three-vessel disease. Eur Heart J. 2019; 40(41):3397-3405. DOI: 10.1093/eurheartj/ehz394. View

van Steen S, Woodward M, Chalmers J, Li Q, Marre M, Cooper M . Haemoglobin glycation index and risk for diabetes-related complications in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. Diabetologia. 2018; 61(4):780-789. PMC: 6448976. DOI: 10.1007/s00125-017-4539-1. View

Kamstrup P . Lipoprotein(a) and Cardiovascular Disease. Clin Chem. 2020; 67(1):154-166. DOI: 10.1093/clinchem/hvaa247. View

Cheng P, Hsu S, Cheng Y, Liu Y . Relationship between hemoglobin glycation index and extent of coronary heart disease in individuals with type 2 diabetes mellitus: a cross-sectional study. PeerJ. 2017; 5:e3875. PMC: 5632534. DOI: 10.7717/peerj.3875. View

Jin J, Sun D, Cao Y, Guo Y, Wu N, Zhu C . Triglyceride glucose and haemoglobin glycation index for predicting outcomes in diabetes patients with new-onset, stable coronary artery disease: a nested case-control study. Ann Med. 2018; 50(7):576-586. DOI: 10.1080/07853890.2018.1523549. View

Gonzalez A, Deng Y, Lane A, Benkeser D, Cui X, Staimez L . Impact of mismatches in HbA vs glucose values on the diagnostic classification of diabetes and prediabetes. Diabet Med. 2019; 37(4):689-696. DOI: 10.1111/dme.14181. View

Ryden L, Grant P, Anker S, Berne C, Cosentino F, Danchin N . ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in.... Eur Heart J. 2013; 34(39):3035-87. DOI: 10.1093/eurheartj/eht108. View

Park S, Kim Y, Hong Y, Moon M, Koo B, Kim T . Up-regulation of the receptor for advanced glycation end products in the skin biopsy specimens of patients with severe diabetic neuropathy. J Clin Neurol. 2014; 10(4):334-41. PMC: 4198715. DOI: 10.3988/jcn.2014.10.4.334. View

10.

Pavelic K, Pavelic Z, Cabrijan T, Karner I, Samarzija M, Stambrook P . Insulin-like growth factor family in malignant haemangiopericytomas: the expression and role of insulin-like growth factor I receptor. J Pathol. 1999; 188(1):69-75. DOI: 10.1002/(SICI)1096-9896(199905)188:1<69::AID-PATH329>3.0.CO;2-P. View

11.

Boudoulas K, Triposciadis F, Geleris P, Boudoulas H . Coronary Atherosclerosis: Pathophysiologic Basis for Diagnosis and Management. Prog Cardiovasc Dis. 2016; 58(6):676-92. DOI: 10.1016/j.pcad.2016.04.003. View

12.

Zhao D, Liu J, Wang M, Zhang X, Zhou M . Epidemiology of cardiovascular disease in China: current features and implications. Nat Rev Cardiol. 2018; 16(4):203-212. DOI: 10.1038/s41569-018-0119-4. View

13.

Leong D, Joseph P, Mckee M, Anand S, Teo K, Schwalm J . Reducing the Global Burden of Cardiovascular Disease, Part 2: Prevention and Treatment of Cardiovascular Disease. Circ Res. 2017; 121(6):695-710. DOI: 10.1161/CIRCRESAHA.117.311849. View

14.

Lebovitz H . Insulin resistance--a common link between type 2 diabetes and cardiovascular disease. Diabetes Obes Metab. 2006; 8(3):237-49. DOI: 10.1111/j.1463-1326.2005.00521.x. View

15.

Hempe J, Liu S, Myers L, McCarter R, Buse J, Fonseca V . The hemoglobin glycation index identifies subpopulations with harms or benefits from intensive treatment in the ACCORD trial. Diabetes Care. 2015; 38(6):1067-74. PMC: 4439529. DOI: 10.2337/dc14-1844. View

16.

Reaven G . Insulin resistance, type 2 diabetes mellitus, and cardiovascular disease: the end of the beginning. Circulation. 2005; 112(20):3030-2. DOI: 10.1161/CIRCULATIONAHA.105.504670. View

17.

Grundy S, Stone N, Bailey A, Beam C, Birtcher K, Blumenthal R . 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2018; 139(25):e1082-e1143. PMC: 7403606. DOI: 10.1161/CIR.0000000000000625. View

18.

Tsugawa Y, Mukamal K, Davis R, Taylor W, Wee C . Should the hemoglobin A1c diagnostic cutoff differ between blacks and whites? A cross-sectional study. Ann Intern Med. 2012; 157(3):153-9. PMC: 3655723. DOI: 10.7326/0003-4819-157-3-201208070-00004. View

19.

Kim M, Jeong J, Yun J, Kwon H, Baek K, Song K . Hemoglobin glycation index predicts cardiovascular disease in people with type 2 diabetes mellitus: A 10-year longitudinal cohort study. J Diabetes Complications. 2018; 32(10):906-910. DOI: 10.1016/j.jdiacomp.2018.08.007. View

20.

Liu S, Hempe J, McCarter R, Li S, Fonseca V . Association between Inflammation and Biological Variation in Hemoglobin A1c in U.S. Nondiabetic Adults. J Clin Endocrinol Metab. 2015; 100(6):2364-71. PMC: 4454807. DOI: 10.1210/jc.2014-4454. View